IDIQ toxicological evaluations of potential medications. Ordering period: 09/12/2023 - 09/11/2028. Nida REF. No. N01DA-23-8939
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N95023D00023
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 2 $2,058,836 obligated
Award facts
- Opportunity
-
- Toxicological Evaluations of Potential Medications to Treat Drug Abuse Pre-Solicitation · 75N95023R00019 · Posted Nov 3, 2022
- Combined order value
-
- $2,058,836 Current, with exercised options
- $2,344,894 Potential, with all options
- Last date to order 62% complete
- IDV ceiling 21% used
- $9,750,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
This indefinite delivery contract (IDC) was awarded by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services, to Sri International, a non-profit research and development institute. The $9.75 million IDC has a period of performance from September 12, 2023 to September 11, 2028 and is for toxicological evaluations of potential medications to support NIDA's mission.
Under this IDC, Sri International has been awarded two task orders so far. The first is a $1.77 million cost-plus-fixed-fee contract for a GLP single dose toxicity study in dogs, and the second is a $571,190 cost-plus-fixed-fee contract for cocaine interaction safety studies in rats. Both task orders fall under the broader scope of the IDC to provide preclinical safety pharmacology and toxicology studies on potential substance use disorder medications to support IND and NDA filings with the FDA. The original solicitation was a small business sources sought notice, but the awards were not set aside for small businesses, reflecting Sri International's status as a large, established non-profit research organization with extensive experience supporting federal agencies through contracts and grants.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N95023D00023?
75N95023D00023 was awarded to Sri International by National Institute on Drug Abuse (National Institutes of Health) on September 12, 2023.
How much is contract 75N95023D00023 worth?
Orders under 75N95023D00023 have obligated $2,058,836. Their combined potential value, with all options, is $2,344,894. 75N95023D00023's own ceiling is $9,750,000.
How many orders have been placed under contract 75N95023D00023?
2 orders have been placed under 75N95023D00023, the latest on September 12, 2024.
Who can order from contract 75N95023D00023?
75N95023D00023 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N95023D00023 competed?
The extent of competition for 75N95023D00023 was full and open competition. The government received 2 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV